Insider Cluster (11 insiders) ·Filed Apr 23, 2026

ABT

ABBOTT LABORATORIES
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $1.1M total
Actionable Insight • Neutral

The insider buying is too small to be material. Focus on the underlying business fundamentals from the Q1 earnings report—guidance was cut, and the stock may face headwinds. Monitor for larger insider transactions or further corporate developments.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
ABT ▲ +10.29% at T+60d
NEUTRAL call ✓ call won +10.29% · α vs SPY +6.56% · entry $91.35 → $100.75
Entry anchored
Apr 28, 2026
via day open
T+1d
-0.79%
call -0.79% · α -1.81%
$90.63
settled 5mo ago
T+5d
-5.62%
call -5.62% · α -8.73%
$86.22
settled 5mo ago
T+20d
-5.60%
call -5.60% · α -11.64%
$86.24
settled 4mo ago
T+60d
+10.29%
call +10.29% · α +6.56%
$100.75
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Insider cluster at Abbott Laboratories shows two open-market purchases totaling $1.13M by the CFO and a director, plus routine non-cash grants to directors. The total cash buying represents only 0.0007% of the company's $161.6B market cap, making it economically trivial. The cluster follows a bearish earnings report on April 16 that lowered full-year guidance, but the insider buying is too small to signal confidence.

Key Financial Metrics

Direction
buying
Total Value
$1.1M
Insiders
11

Key Facts

  • CFO Philip Boudreau purchased $201,300 worth of shares on April 23 at $91.50
  • Director Daniel Starks purchased $926,537 worth of shares on April 27 at $92.65
  • 14 other insider transactions were non-cash grants (code A) or discretionary trades (code I), totaling $0 in open-market purchases
  • Total cash purchases: ~$1.13M, 0.0007% of market cap
  • Cluster occurred 7-11 days after a bearish Q1 earnings miss and guidance cut

Financial Impact

Negligible; $1.13M in insider buying is trivial relative to $161.6B market cap

Risk Factors

  • No material risks from this cluster; the buying is immaterial

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
74% bullish (35 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ABT-1777419507088
23 reports for ABT
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +17.16%Jul 1, 2026
Filters
Rows
Reports for ABT — sortable, filterable
TypeNow
Oct 2, 2026
today
ANALYST-UPGRADE
BULLISH ★ 4/10
$98.00 awaiting T+5awaiting T+5—$96.46 (−1.57%)
Oct 2, 2026
today
ANALYST-UPGRADE
BULLISH ★ 4/10
$98.00 awaiting T+5awaiting T+5—$96.46 (−1.57%)
Sep 14, 2026
18d ago
Court Ruling
NEUTRAL ★ 1/10
$103.09 $102.98▼ −0.11%▼ −1.77%$96.46 (−6.43%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 2/10
$109.72 $112.68▲ +2.70%▲ +3.10%$96.46 (−12.09%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 1/10
$109.72 $112.68▲ +2.70%▲ +3.10%$96.46 (−12.09%)
Jul 31, 2026
9w ago
Institutional Cluster
MIXED ★ 4/10
$105.70 $107.81▲ +2.00%▼ −1.51%$96.46 (−8.74%)
Jul 31, 2026
9w ago
Court Ruling
NEUTRAL ★ 2/10
$105.70 $107.81▲ +2.00%▼ −1.51%$96.46 (−8.74%)
Jul 24, 2026
10w ago
Court Ruling
BULLISH ★ 5/10
$103.06 $105.61▲ +2.47%▲ +2.10%$96.46 (−6.40%)
Jul 16, 2026
11w ago
8-K
BULLISH ★ 6/10
$98.83 $100.75▲ +1.94%▲ +3.61%$96.46 (−2.40%)
Jul 14, 2026
11w ago
Court Ruling
NEUTRAL ★ 3/10
$88.96 $101.66▲ +14.28%▲ +15.57%$96.46 (+8.43%)
Showing 10 of 23

US Market Status

Market Open — Closes in 3h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 28, 2026